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Abstract
Background Arrhythmogenic right ventricular cardiomyop-
athy/dysplasia (ARVC/D) is a myocardial disease that
predominantly affects the right ventricle (RV). Its hallmark
feature is fibrofatty replacement of the RV myocardium.
Apoptosis in ARVC/D has been proposed as an important
process that mediates the slow, ongoing loss of heart
muscle cells which is followed by ventricular dysfunction.
We aimed to establish whether cardiac apoptosis can be
assessed noninvasively in patients with ARVC/D.
Methods Six patients fulfilling the ARVC/D criteria were
studied. Regional myocardial apoptosis was assessed with
99mTc-annexin V scintigraphy.
Results Overall, the RV wall showed a higher
99mTc-annexin
V signal than the left ventricular wall (p=0.049) and the
interventricular septum (p=0.026). However, significantly
increased uptake of
99mTc-annexin V in the RV was present
in only three of the six ARVC/D patients (p=0.001,
compared to
99mTc-annexin V uptake in the RV wall of the
other three patients).
Conclusion Our results are suggestive of a chamber-
specific apoptotic process. Although the role of apoptosis
in ARVC/D is unsolved, the ability to assess apoptosis
noninvasively may aid in the diagnostic course. In addition,
the ability to detect apoptosis in vivo with
99mTc-annexin V
scintigraphy might allow individual monitoring of disease
progression and response to diverse treatments aimed at
counteracting ARVC/D progression.
Keywords Arrhythmogenic right ventricle
cardiomyopathy/dysplasia.Scintigraphy.
Apoptosis. 99mTc-annexin V scintigraphy
Abbreviations
99mTc technetium 99m
ARVC/D arrhythmogenic right ventricular
cardiomyopathy/dysplasia
IVS inter-ventricular septum
LV left ventricle
PS phosphatidylserine
ROI region of interest
RV right ventricle
VT ventricular tachycardia
Introduction
Arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC/D) is a disease that predominantly affects the right
ventricle (RV), although biventricular involvement may
occur in advanced disease [1]. ARVC/D is characterized by
structural derangements that may cause a broad range of
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variable and incomplete in most patients, confounding both
the diagnostic process and clinical management, particular-
ly during early disease stages [2].
The histopathological hallmark of ARVC/D is fibrofatty
replacement of the RV myocardium. Apoptosis has been
proposed as an important mechanism that mediates the
slow, ongoing loss of heart muscle cells which is followed
by ventricular dysfunction [3]. How fibrofatty replacement
and apoptosis are related in ARVC/D is a matter of
speculation. The possibility to detect apoptosis in vivo in
ARVC/D may lead to a better understanding of the
pathophysiological mechanism underlying disease progres-
sion[4]. In vivo imaging of cardiac apoptosis with the use of
99mTc-annexin V has been proven feasible, as
99mTc-annexin
V binds to exposed phosphatidylserine (PS) on the outer
surface of apoptotic cells [5]. Accordingly,
99mTc-annexin V
has been effectively used to noninvasively visualize regions
of apoptosis in patients with various pathologies [6–9], as
well as in experimental models [10, 11]. We aimed to
establish whether cardiac apoptosis can be assessed non-
invasively in patients with ARVC/D.
Methods
Patients
The institutional review board approved the study protocol
and informed consent was obtained from all study subjects.
Six ARVC/D patients were examined. The patients, who
fulfilled the ARVC/D Task Force criteria [12], were
randomly taken from the cohort of ARVC/D patients at
our institution. Patients were evaluated when they were in a
clinically stable condition (no ventricular tachyarrhythmias
or heart failure symptoms during the 2 months prior to
inclusion). In all patients, molecular genetic analysis was
performed and focused on known mutations related to
ARVC/D; these included plakophilin-2 (PKP2), desmopla-
kin (DSP), desmoglein-2 (DSG2), desmocollin-2 (DSC2),
plakoglobin (JUP), and transmembrane protein 43
(TMEM43) [13, 14]. No patient had a history of coronary
artery disease, diabetes or hypertension.
Scintigraphy
Patients were intravenously injected with 600 MBq of
99mTc HYNIC-rh-annexin V (
99mTc-annexin V), and 4 h
after administration, single photon emission computed
tomography (SPECT) scans were acquired using a dual-
headed gamma camera equipped with a 3/8” NaI(Tl) crystal
and combined with a low-dose CT scanner (Infinia; General
Electric Medical Systems, Haifa, Israel). SPECTscans were
acquired with low-energy, high-resolution collimators, a
15% energy window on the 140 keV photopeak, according
to a step-and-shoot protocol with a total of 90 frames and
30 s per frame in a 128×128 matrix and a zoom of 1.28.
SPECT images were iteratively reconstructed (OSEM) and
corrected for attenuation using the low-dose CT scans from
the Infinia scanner (no intravenous contrast material).
Analysis of scintigraphic data
To define the anatomical borders of the myocardium
within the thorax, anatomical tomographic images are
essential and the low-dose CT images of the Infinia
could not be used for this purpose. Therefore, tomo-
graphic anatomical images from contrast-enhanced CT or
cardiac MR imaging performed prior to implantable
cardioverter defibrillator (ICD) implantation and within
2m o n t h so f
99mTc-annexin V scintigraphy were reviewed
for all subjects. To align the anatomical images with the
SPECT data, first the matrix size of the anatomical images
was adjusted to the matrix size of the SPECT data
(128×128) and second the images were automatically
aligned (MultiModality; HERMES Medical Solutions,
Sweden). To semiquantify
99mTc-annexin V myocardial
uptake, three regions of interest (ROI) including the RV
wall, interventricular septum (IVS) and left ventricle (LV)
f r e ew a l lw e r ed r a w no nt h r e es u m m e dm i d - m y o c a r d i a l
horizontal long axis anatomical images. To correct for
background activity (i.e. nonspecific uptake), a separate
region was drawn on both lungs. As there were no
differences between the two lung regions, these values
were aggregated to one value (mean counts per pixel). The
ROIs were determined on the anatomical images and were
subsequently copied to the aligned SPECT images.
99mTc-
annexin V uptake in each separate ROI was calculated as
the ratio of the mean counts per pixel in the specific
myocardial region to the mean counts per pixel in the total
myocardium (i.e. the sum of all three ROIs). Both the
regional and the total myocardial activity were corrected
for background activity by subtraction of nonspecific
uptake. The attenuation-corrected SPECT data were used
for analysis. The reader was blinded to the clinical
information.
Follow-up
Long-term follow-up data were obtained from at least one of
three sources: visit to the outpatient clinic; review of the
patient’s hospital records; personal communication with the
patient’s physician.Thisanalysisfocusedontheoccurrenceof
ventricular arrhythmias, appropriate ICD discharge, and
sudden cardiac death. One patient was lost to follow-up. The
mean follow-up was 27±8 months (range 18–57 months).
Eur J Nucl Med Mol Imaging (2011) 38:1500–1506 1501T
a
b
l
e
1
C
l
i
n
i
c
a
l
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
p
a
t
i
e
n
t
s
w
i
t
h
A
R
V
C
/
D
P
a
t
i
e
n
t
n
o
.
G
e
n
d
e
r
A
g
e
a
t
s
c
i
n
t
i
g
r
a
p
h
y
(
y
e
a
r
s
)
S
y
m
p
t
o
m
s
a
t
d
i
a
g
n
o
s
i
s
A
g
e
a
t
d
i
a
g
n
o
s
i
s
(
y
e
a
r
s
)
M
u
t
a
t
i
o
n
M
e
d
i
c
a
t
i
o
n
A
R
V
C
/
D
T
a
s
k
F
o
r
c
e
c
r
i
t
e
r
i
a
F
a
m
i
l
y
h
i
s
t
o
r
y
E
C
G
d
e
p
o
l
a
r
i
z
a
t
i
o
n
/
c
o
n
d
u
c
t
i
o
n
E
C
G
r
e
p
o
l
a
r
i
z
a
t
i
o
n
A
r
r
h
y
t
h
m
i
a
s
R
V
d
y
s
f
u
n
c
t
i
o
n
D
i
s
e
a
s
e
c
o
n
f
i
r
m
e
d
a
t
n
e
c
r
o
p
s
y
(
m
a
j
o
r
)
S
u
d
d
e
n
c
a
r
d
i
a
c
d
e
a
t
h
(
m
i
n
o
r
)
a
A
R
V
C
/
D
(
m
i
n
o
r
)
E
p
s
i
l
o
n
w
a
v
e
(
m
a
j
o
r
)
L
a
t
e
p
o
t
e
n
t
i
a
l
(
m
i
n
o
r
)
N
e
g
a
t
i
v
e
T
w
a
v
e
(
m
i
n
o
r
)
L
B
B
B
-
V
T
(
m
i
n
o
r
)
>
1
,
0
0
0
P
V
C
/
2
4
h
(
m
i
n
o
r
)
S
e
v
e
r
e
(
m
a
j
o
r
)
M
i
l
d
(
m
i
n
o
r
)
1
M
2
4
S
y
n
c
o
p
e
2
1
P
K
P
2
:
S
o
t
a
l
o
l
−
+
+
−
+
+
+
−
−
+
C
7
9
6
R
b
2
F
5
5
V
T
4
9
N
o
–
−
+
+
−
N
A
+
+
−
−
+
3
F
4
8
V
T
3
8
N
o
S
o
t
a
l
o
l
−
−
−
−
N
A
+
+
N
A
−
+
4
M
3
3
V
T
3
0
N
o
S
o
t
a
l
o
l
−
−
+
−
−
+
+
N
A
−
+
5
M
1
9
V
T
1
6
N
o
S
o
t
a
l
o
l
−
−
−
−
N
A
+
-
N
A
−
+
6
M
4
1
V
T
2
7
D
S
G
2
:
–
−
−
−
−
+
+
+
N
A
+
−
T
3
3
5
A
c
L
B
B
B
l
e
f
t
b
u
n
d
l
e
b
r
a
n
c
h
b
l
o
c
k
,
N
A
n
o
t
a
n
a
l
y
s
e
d
,
P
V
C
p
r
e
m
a
t
u
r
e
v
e
n
t
r
i
c
u
l
a
r
c
o
m
p
l
e
x
.
a
D
e
a
t
h
b
e
f
o
r
e
3
5
y
e
a
r
s
o
f
a
g
e
d
u
e
t
o
s
u
s
p
e
c
t
e
d
A
R
V
C
/
D
.
b
C
7
9
6
R
m
i
s
s
e
n
s
e
m
u
t
a
t
i
o
n
i
n
p
l
a
k
o
p
h
i
l
i
n
-
2
.
c
T
3
3
5
A
m
i
s
s
e
n
s
e
m
u
t
a
t
i
o
n
i
n
d
e
s
m
o
g
l
e
i
n
-
2
.
1502 Eur J Nucl Med Mol Imaging (2011) 38:1500–1506Statistical analysis
Data are presented as means ± SD. Mean values were
compared for differences using the (un)paired Student’s t-
test when appropriate. For multiple comparisons, means
were compared for differences using analysis of variance
(ANOVA) with a post-hoc Bonferroni correction (SPSS for
Windows 16.0.2.1; SPSS, Chicago, IL). A p value <0.05 was
considered to indicate statistical significance.
Results
Clinical spectrum
Table 1 summarizes the demographic/clinical data. All
patients fulfilled the ARVC/D Task Force criteria [12]. Their
mean age at clinical presentation was 36.7±13.9 years (range
19–55 years) and 33% (two) were women. In five patients,
ventricular tachycardia (VT) with left bundle branch block
morphology was the first expression of ARVC/D. One
patient presented with syncope. Two patients had a positive
family history of premature sudden cardiac death. All
p a t i e n t sh a dn o r m a lL Vf u n c t i o nb ye c h o c a r d i o g r a p h ya n d
all patients had an ICD. All patients had a history of
haemodynamically unstable VT. Four patients were on
antiarrhythmic agents. One patient had the C796R mutation
in PKP2, while one had the T335A mutation in DSG2. In the
remaining patients, no DNA mutations were found. One
patient (patient 6) had severe segmental dilatation of the RV
on echocardiography (major ARVC/D Task Force criterion
[12]). The other five patients had regional RV hypokinesia
(patients 2, 3 and 5), mild segmental dilatation of the RV
(patient 4) and mild global RV dilatation with normal LV
function (patient 1) on echocardiography (minor ARVC/D
Task Force criteria [12]).
Myocardial
99mTc-annexin V uptake
Figure 1 shows a typical example of a patient who
exhibited increased
99mTc-annexin V uptake in the RV wall
(patient 2). Overall, the RV wall showed a higher
99mTc-
annexin V uptake (1.328±0.437) than the LV wall (0.936±
0.175, p=0.049) or the IVS (0.902±0.222, p=0.026). There
was no difference in
99mTc-annexin V uptake between the
LV wall and the IVS (p=0.986). However, the overall
higher uptake of
99mTc-annexin V in the RV wall could be
explained by the fact that 50% of patients (patients 3, 5 and
6) showed increased
99mTc-annexin V uptake in the RV
compared to the other three patients (patients 1, 2 and 4;
1.788±0.133 vs 0.983±0.034 respectively, p=0.001;
Fig. 2).
Within 2 months of
99mTc-annexin V scintigraphy,
cardiac MR images were available in three patients
(patients 2, 3 and 4). Only patient 3 showed increased
uptake of
99mTc-annexin V. The increased uptake of
99mTc-
annexin V was located in the lateral wall of the RV, while
the MR images showed an overall dilated RV with regional
dyskinesia of the apex. It is therefore not possible to draw
any conclusions as to a potential correlation between
cardiac MRI RVabnormalities and the location of increased
uptake of
99mTc-annexin V.
Follow-up
The extent of
99mTc-annexin V uptake in the RV wall did
not distinguish patients with arrhythmias within 2 years
after
99mTc-annexin V scintigraphy from those without, nor
did it distinguish patients in whom a gene mutation was
found from those in whom it was not (Table 2).
Discussion
Apoptosis is a significant pathophysiological feature of
ARVC/D and is a consistent post-mortem finding in both
the RV and LV [1, 15]. In this study,
99mTc-annexin V
scintigraphy was performed with the purpose of establish-
ing whether apoptosis can be visualized in vivo in patients
with ARVC/D. Our results demonstrated increased
99mTc-
annexin V uptake in the RV free wall of three ARVC/D
patients, suggestive of RV-specific apoptotic activity in
RV wall
LV wall
IVS
Fig. 1 Coregistered transaxial
images of patient 3 (left cardiac
MR image, right
99mTc-annexin
SPECT scintigraphy image).
There is increased
99mTc-
annexin V uptake in the RV wall
(IVS interventricular septum, LV
left ventricular free wall)
Eur J Nucl Med Mol Imaging (2011) 38:1500–1506 1503these patients. The variation in myocardial uptake of
99mTc-
annexin V between patients is not surprising and might
partly be explained by the random distribution and the
episodic nature of the apoptotic process [16]. Furthermore,
patients differed with respect to the time since diagnosis
and severity of morphological abnormalities. These varia-
tions were probably reflected by differences in myocardial
uptake of
99mTc-annexin V.
All our ARVC/D patients had a history of documented
VT episodes. Mallat et al. speculated that apoptosis in
ARVC/D might result from repetitive ventricular tachyar-
rhythmia episodes [15]. Furthermore, apoptotic myocytes
are frequently found in regions of the myocardium which
are not subjected to invasion by adipocytes and fibrosis,
suggesting that the loss of myocytes through apoptosis
occurs as a primary process before adipocytes and fibrous
tissues fill the vacant cellular space. Also, Valente et al.
have reported that apoptosis is present in endomyocardial
biopsy samples of patients with ARVC/D, especially in the
early symptomatic phase of the disease [17].
The exposure of PS on the cell surface is a general
marker of apoptotic cells. Externalization of nonapoptotic
PS is induced by several activation stimuli, including
engagement of immunoreceptors. Externalized PS is ob-
served in apoptotic, injured, infected, senescent and
necrotic cells, and becomes a target for recognition by
phagocytes [18–20]. Thus, in addition to acting as a marker
of apoptosis, annexin V may be a marker of inflammation
and cell stress. Accordingly, the myocardial uptake of
99mTc-annexin V is most likely not only a marker of
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
LV wall IVS RV wall
ARVC/D 1
ARVC/D 2
ARVC/D 3
ARVC/D 4
ARVC/D 5
ARVC/D 6
Fig. 2
99mTc-annexin uptake in the RV wall, IVS and LV wall
calculated as the ratio of the uptake (mean counts per pixel) in the
vvparticularmyocardial regiontotheuptake inthe totalmyocardium (i.e.
the sum of all three ROIs)
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1504 Eur J Nucl Med Mol Imaging (2011) 38:1500–1506apoptosis, but may also partly reflect local inflammation.
Patchy inflammatory infiltrates in RV are consistently
reported in ARVC/D, both in in vitro and in in vivo
examinations [3, 21, 22].
Patchy cell death combined with inflammatory infil-
tration is a common histological finding in ARVC/D
[23]. The inflammation might be a reaction to proinflam-
matory cytokines induced by cell death and/or apoptosis or
caused by an infectious myocarditis (e.g. viral infection)
[21, 24]. Although it is most likely that these factors are, at
least to some extent, interrelated, it is not known whether
there is a causal relationship between inflammation and
cell death in ARVC/D. However, it remains unclear
whether myocarditis in ARVC/D is disease-initiating (a
primary event) or a reaction to processes initiated by
ARVC/D.
Study limitations and clinical usefulness
The first limitation of our study is the small number of
patients. The observation of
99mTc-annexin V myocardial
uptake in three out of six patients might be explained by the
random distribution and the episodic nature of the apoptotic
process. Second, no cardiac biopsies were obtained.
Therefore, a validation of the
99mTc-annexin V myocardial
uptake with histology was not possible.
Recently modification of the highly specific ARVC/D
Task Force criteria (published in 1994) has been proposed
[25]. The revision incorporates new knowledge and
technology to improve especially the sensitivity of the Task
Force criteria without changing the high specificity.
However, at the time of patient inclusion the 1994 criteria
were used [12]. As expected, because of the relatively
unchanged specificity, reevaluation of the patients included
in our study according to the new criteria did not change
the clinical diagnosis in any patient.
Conclusion
Apoptosis may be detected noninvasively in ARVC/D, and
this may lead to a better understanding of the role of
apoptosis in the pathophysiology of ARVC/D. Whether it
will allow monitoring of the disease course or the response
to various treatments aimed at counteracting disease
progression remains to be studied.
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